Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
23-Valent Pneumococcal Polysaccharide Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global 23-Valent Pneumococcal Polysaccharide Vaccine market is projected to reach US$ 1993.7 million in 2034, increasing from US$ 1139.5 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Demand from For Children (Over 2 Years Old) and For Adult are the major drivers for the industry.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global 23-Valent Pneumococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax
Segment by Type
Single Dose Vial
Pre-filled Syringe
For Children (Over 2 Years Old)
For Adult
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the 23-Valent Pneumococcal Polysaccharide Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of 23-Valent Pneumococcal Polysaccharide Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the 23-Valent Pneumococcal Polysaccharide Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of 23-Valent Pneumococcal Polysaccharide Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, 23-Valent Pneumococcal Polysaccharide Vaccine introduction, etc. 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of 23-Valent Pneumococcal Polysaccharide Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
23-Valent Pneumococcal Polysaccharide Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global 23-Valent Pneumococcal Polysaccharide Vaccine market is projected to reach US$ 1993.7 million in 2034, increasing from US$ 1139.5 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Demand from For Children (Over 2 Years Old) and For Adult are the major drivers for the industry.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global 23-Valent Pneumococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
For Children (Over 2 Years Old)
For Adult
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the 23-Valent Pneumococcal Polysaccharide Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of 23-Valent Pneumococcal Polysaccharide Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the 23-Valent Pneumococcal Polysaccharide Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of 23-Valent Pneumococcal Polysaccharide Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, 23-Valent Pneumococcal Polysaccharide Vaccine introduction, etc. 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of 23-Valent Pneumococcal Polysaccharide Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices